Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for Relapsed/refractory Acute Myeloid Leukemia

NCT06741722 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.

NCT NCT06741722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06741722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for Relapsed/refractory Acute Myeloid Leukemia
Lead sponsor
Beijing 302 Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
October 31, 2024
Completion date
December 31, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml, refractory acute myeloid leukemia, relapsed acute myeloid leukemia